NISHITH.TV
  • Mumbai
  • Silicon Valley
  • Bengaluru
  • Singapore
  • Mumbai BKC
  • New Delhi
  • Munich
  • New York

Locations

  • Mumbai
  • Silicon Valley
  • Bengaluru
  • Singapore
  • Mumbai BKC
  • New Delhi
  • Munich
  • New York
  • Content
  • Home
  • ABOUT US
  • NDA in the Media
  • Areas of Service
  • Research and Articles
  • Opportunities
  • Contact
  • NDACloud
  • Client Access
  • Member Access
  • Events and Calender
  • How we perform
  • Knowledge anywhere, anytime
  • See our recent deals
  • Up to date legal developments
  • Case studies in M&A

Research and Articles

HTMLPDF

  • Research at NDA
  • Research Papers
  • Research Articles
  • NDA Think Tanks
  • NDA Hotline
  • New Ali Gunjan
  • Japan Desk ジャパンデスク

NDA-Hotline


  • Debt Funding in India Series
  • Private Equity Corner
  • The Startups Series
  • Court Corner
  • Investment Funds: Monthly Digest
  • Insolvency and Bankruptcy Hotline
  • Deal Destination
  • New Publication
  • M&A Interactive
  • Lit Corner
  • Private Debt Hotline
  • Food & Beverages Hotline
  • Companies Act Series
  • Gaming Law Wrap
  • Private Client Wrap
  • GIFT City Express
  • Regulatory Hotline
  • Capital Markets Hotline
  • Tax Hotline
  • Corpsec Hotline
  • Dispute Resolution Hotline
  • M&A Hotline
  • Pharma & Healthcare Update
  • Competition Law Hotline
  • HR Law Hotline
  • IP Hotline
  • Telecom Hotline
  • FEMA Hotline
  • Social Sector Hotline
  • iCe Hotline
  • SEZ Hotline
  • Media Hotline
  • Funds Hotline
  • Education Sector Hotline
  • International Trade Hotlines
  • Other Hotline
  • Real Estate Update
  • Realty Check
  • White Collar and Investigations Practice
  • Legal Update
  • IP Lab
  • Cross Examination
  • Technology & Tax Series
  • Technology Law Analysis
  • Yes, Governance Matters.
  • Financial Service Update
  • Japan Desk ジャパンデスク

Pharma & Healthcare Update

June 24, 2015

Pharma Alert


  • Supreme court bars Glenmark from manufacturing allegedly infringing copies of MSD diabetes drug
  • State bans online sale of prescription drugs
  • Advertising prescription drugs is now prohibited without prior government permission

SUPREME COURT BARS GLENMARK FROM MANUFACTURING ALLEGEDLY INFRINGING COPIES OF MSD DIABETES DRUG

The Supreme Court of India has barred Glenmark Pharmaceuticals (Glenmark) from making and selling alleged infringing copies of Merck, Sharp and Dohme's (MSD) diabetes drug until further order.

MSD filed a patent infringement suit in 2013 against Glenmark before a single judge of the Delhi High Court for using its patented product, Sitagliptin, as an active pharmaceutical ingredient without permission in its product portfolio. It also applied for a temporary injunction restraining Glenmark from manufacturing and selling the allegedly infringing drugs, Zita and Zitamet. The temporary injunction was refused by the single judge. MSD appealed against the single judge's order before a Division Bench of the Delhi High Court and was able to obtain a favourable order restraining Glenmark from manufacturing and selling the allegedly infringing drugs. Glenmark appealed against the order of the Division Bench before the Supreme Court and was able to obtain a stay on the order of the Division Bench.

On 15 May 2015, the Supreme Court lifted its stay on the Divison Bench's order on the ground of maintaining balancing equities between the parties, while also maintaining public interest. Glenmark can no longer manufacture the allegedly infringing drugs, but was permitted to continue to sell drugs which were already on the market.

This is a positive decision by the Supreme Court, as it has attempted to balance the interests of all the parties in a patent infringement suit.

STATE BANS ONLINE SALE OF PRESCRIPTION DRUGS

The State Drug Licensing Authority of the State of Telangana (the Telangana FDA) has reportedly banned the online sale of prescription drugs.

The Telangana FDA has reportedly issued a press release banning the operation of the online sale of prescription drugs.

Under applicable law, prescription drugs have to be dispensed under the supervision of a registered pharmacist and against an original prescription of a registered medical practitioner. The reason behind the ban was non-compliance with these conditions.

These legal requirements of sale of prescription drugs are laid down under the Drugs and Cosmetics Rules, 1945 (made, centrally, under the Drugs and Cosmetics Act, 1940) which is administered in all the States of India by the State level drug licensing authorities.

The business of online pharmacies is likely to be adversely affected if other state licensing authorities replicate the decision of the Telangana FDA..

ADVERTISING PRESCRIPTION DRUGS IS NOW PROHIBITED WITHOUT PRIOR GOVERNMENT PERMISSION

An amendment in the law has prohibited manufacturers who produce prescription drugs from advertising the drugs without prior central government approval.

The Ministry of Health and Family Welfare has amended the Drugs and Cosmetics Rules, 1945 (Rules) which regulate the manufacture, import, distribution and sale of drugs. After the amendment, a manufacturer of drugs listed under Schedules H, H1 and X to the Rules is required to obtain prior approval of the Ministry of Health and Family Welfare to advertise the drugs.

Schedule H sets out all prescription drugs. Schedule H1 sets out various antibiotics. Schedule X sets out a number of narcotic and psychotropic drugs.

It is believed that this step may have been taken to curb self-medication by consumers.

 

* Reproduced from Practical Law with the permission of the publishers.

 

– Khushboo Baxi & Anay Shukla

You can direct your queries or comments to the authors

Mission and Vision


Distinctly Different

What's New


Law of Damages in India
New Publication: July 02,2022
Mid-year Regulatory Update 2022: Food Industry in India
Pharma & Healthcare Update : July 01,2022

Events


Webinars

Sustainable Mobility: Opportunities and Challenges
June 09,2022 - June 09,2022

This event is over. For event material please click here


Seminar

Navigating Disputes in India
February 26,2020 - February 26,2020

This event is over. For event material please click here


Round Table

Investing In Net Zero
July 14,2022 - July 14,2022

News Roundup


News Articles

Impact of Supreme Court’s new covidvaccination ruling on India’s employers
May 13,2022

Quotes

Are you a social media influencer or doctor? Here's how the new TDS rules will impact you
June 26,2022

Newsletters


New Publication

Law of Damages in India
July 02,2022

Pharma & Healthcare Update

Mid-year Regulatory Update 2022: Food Industry in India
July 01,2022

Competition Law Hotline

NCLAT Order in Amazon/FCPL Is a Missed Opportunity for Answering Substantive Questions of Law
July 01,2022

  • Disclaimer
  • Content
  • Feedback
  • Walkthrough
  • Subscribe
Nishith Desai Associates@2016 All rights reserved.